RESUMO
Formoterol para tratamento de exacerbações leves a moderadas de asma em crianças e adolescentes: estudo randomizado comparativo com a terbutalina. Com objetivo de verificar a eficácia do formoterol no tratamento da exacerbação de asma, realizou-se um estudo duplo cego, randomizado em pacientes pediátricos (9,922,5anos) atendidos no pronto socorro. Utilizou-se até 3 doses de formoterol 12mcg ou terbutalina 0,5mg. Foram avaliados: escore clínico, oximetria de pulso e espirometria no início e 15 minutos após cada dose / In order to verify the efficacy of formoterol in the treatment of asthma exacerbations, a randomized, double-blind study was conducted with pediatric patients (9,922,5yrs) at the ED. Patients received up to 3 doses of formoterol 12 µg or terbutaline 0.5 mg. Clinical score, pulse oximetry and spirometry were evaluated in the beginning and 15 min after each dose...
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Asma/terapia , Broncodilatadores/uso terapêutico , Criança , Método Duplo-Cego , Testes de Função Respiratória , Resultado do TratamentoRESUMO
Cystic fibrosis is a genetic disease usually diagnosed by abnormal sweat testing. We report a case of an 18-year-old female with bronchiectasis, chronic P. aeruginosa infection, and normal sweat chloride concentrations who experienced rapid decrease of lung function and clinical deterioration despite treatment. Given the high suspicion ofcystic fibrosis, broad genotyping testing was performed, showing a compound heterozygous with deltaF508 and 3849+10kb C->T mutations, therefore confirming cystic fibrosis diagnosis. Although the sweat chloride test remains the gold standard for the diagnosis of cystic fibrosis, alternative diagnostic tests such as genotyping and electrophysiologic measurements must be performed if there is suspicion of cystic fibrosis, despite normal or borderline sweat chloride levels